Login / Signup

Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease.

George J KahalyPeter J DolmanJan WolfBert C GiersHeike M ElfleinAmy P JainAshok SrinivasanLubomir HadjiiskiDavid JordanElizabeth A BradleyMarius N StanAnja EcksteinSusanne PitzChristian VorländerSara T WesterJohn NguyenNancy TuckerMarco Sales-SanzSteven E FeldonChristine C NelsonIsabelle HardyMaravillas Abia-SerranoPhilip TedeschiJonathan M JanesJing XuPeter VueWilliam L MaciasRaymond S Douglas
Published in: The Journal of clinical endocrinology and metabolism (2023)
These results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.
Keyphrases
  • placebo controlled
  • double blind
  • phase iii
  • phase ii
  • clinical trial
  • study protocol
  • phase ii study
  • open label
  • squamous cell carcinoma
  • randomized controlled trial